Geoffrey Martha - Medtronic PLC President
| MDT Stock | USD 86.54 0.27 0.31% |
President
Mr. Geoffrey S. Martha is Executive Vice President and President Restorative Therapies Group., subsidiary of the Company. since June 2015 since 2020.
| Age | 54 |
| Tenure | 4 years |
| Address | Building Two, Galway, Ireland |
| Phone | 353 1 438 1700 |
| Web | https://www.medtronic.com |
Latest Insider Transactions
Martha previously served as Senior Vice President of Strategy and Business Development of the Company beginning in January 2015 and of Medtronic, Inc. beginning in August 2011. Prior to that, he served as Managing Director of Business Development at GE Healthcare from April 2007 to July 2011; General Manager for GE Capital Technology Finance Services from November 2003 to March 2007; Senior Vice President, Business Development for GE Capital Vendor Financial Services from February 2002 to October 2003; General Manager for GE Capital Colonial Pacific Leasing from February 2001 to January 2002; and Vice President, Business Development for Potomac Federal, the GE Capital federal financing investment bank from May 1998 to January 2001.Medtronic PLC Management Efficiency
The company has Return on Asset of 0.0442 % which means that on every $100 spent on assets, it made $0.0442 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0795 %, implying that it generated $0.0795 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.11 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 11.3 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 94.5 B in 2024Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Roger Bird | Abbott Laboratories | 63 | |
| Robert Fletcher | Stryker | 53 | |
| Maulik Nanavaty | Boston Scientific Corp | ||
| Ivan Tornos | Zimmer Biomet Holdings | 49 | |
| Brent Ladd | Stryker | N/A | |
| Timothy Scannell | Stryker | 59 | |
| John Kapples | Insulet | 64 | |
| Jared Watkin | Abbott Laboratories | 56 | |
| Derek Davis | Zimmer Biomet Holdings | 51 | |
| Jonathan Monson | Boston Scientific Corp | N/A | |
| Daniel Salvadori | Abbott Laboratories | 45 | |
| William Berry | Stryker | 58 | |
| Ian Meredith | Boston Scientific Corp | 64 | |
| Donald Payerle | Stryker | N/A | |
| Leigh Vosseller | Tandem Diabetes Care | 50 | |
| Glenn Boehnlein | Stryker | 62 | |
| Brian White | Stryker | N/A | |
| Michael Spears | Insulet | 59 | |
| Viju Menon | Stryker | 56 | |
| Charles Alpuche | Insulet | 64 | |
| Wendy Carruthers | Boston Scientific Corp | 52 | |
Management Performance
| Return On Equity | 0.0795 | ||||
| Return On Asset | 0.0442 |
Medtronic PLC Leadership Team
Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brett Wall, Executive Vice President and President Restorative Therapies Group | ||
| Jennifer Kirk, Chief Accounting Officer, Global Controller | ||
| Bradley Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Scott Cundy, Senior Officer | ||
| Scott Donnelly, Lead Independent Director | ||
| Kenneth Washington, Senior Officer | ||
| Richard Anderson, Lead Independent Director | ||
| Ryan Weispfenning, Vice President - Investor Relations | ||
| Mark Ploof, Senior Services | ||
| Sean Lennon, Chief Officer | ||
| Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group | ||
| Elizabeth Nabel, Independent Director | ||
| Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer | ||
| James Lenehan, Independent Director | ||
| Mei Jiang, Senior Innovation | ||
| John Liddicoat, Executive Vice President and President Americas Region | ||
| Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group | ||
| Kevin Lofton, Independent Director | ||
| Craig Arnold, Independent Director | ||
| Kendall Powell, Lead Independent Director | ||
| Olaf Hedrich, Chief Officer | ||
| Sally Saba, Chief Inclusion and Diversity Officer | ||
| Denise OLeary, Independent Director | ||
| Omar Ishrak, Chairman of the Board, Chief Executive Officer | ||
| Brad Lerman, Senior Vice President General Counsel, Corporate secretary | ||
| Matt Walter, Chief Officer | ||
| Frank Chan, President Monitoring | ||
| Joon Hurh, VP Pacific | ||
| Torod Neptune, Senior Officer | ||
| Ivan Fong, General VP | ||
| Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio | ||
| Gary Corona, Senior CFO | ||
| Carol Surface, Chief Human Resource Officer, Senior Vice President | ||
| Karen Parkhill, Chief Financial Officer, Executive Vice President | ||
| Que Dallara, Executive Unit | ||
| Gregory Smith, Executive Chain | ||
| Michael Leavitt, Independent Director | ||
| Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group | ||
| Robert Hopkins, Senior Strategy | ||
| Randall Hogan, Independent Director | ||
| Andrea Goldsmith, Independent Director | ||
| Robert Hoedt, Executive Vice President and President - EMEA Region | ||
| MSc MD, Medical Scientific | ||
| Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group | ||
| MPH MD, Chief Business |
Medtronic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0795 | ||||
| Return On Asset | 0.0442 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 131.31 B | ||||
| Shares Outstanding | 1.28 B | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 85.40 % | ||||
| Number Of Shares Shorted | 10.18 M | ||||
| Price To Earning | 20.44 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Medtronic Stock Analysis
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.